HCPCS Level II code J2788 denotes a minidose injection of Rho(D) immune globulin, human — 50 micrograms (250 international units) — used to prevent Rh sensitization after exposure to Rh-positive blood. Nationally, this code is important for obstetric and post-exposure prophylaxis workflows and for appropriate billing of a commonly administered immunoglobulin product. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of clinical context, typical sites of service, and billing considerations tied to J2788. The publication provides benchmark information on coverage patterns and reimbursement groupings, highlights any recent policy updates relevant to Rho(D) immune globulin administration, and clarifies coding nuances for the minidose product. The report is intended for revenue cycle managers, billing professionals, and clinical leaders seeking a national perspective on handling claims for Rho(D) immune globulin minidose injections.